Trial · NCT04344600
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
NCT04344600, Phase 2, Terminated, Johns Hopkins University; results first posted 2022-07-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection. Trials, record NCT04344600. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04344600
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
- NCT number
- NCT04344600
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Sars-CoV-2 Infection
- Interventions
- Peginterferon lambda alfa-1a subcutaneous injection, Saline
- First posted
- 2020-04-14
- Last updated
- 2022-07-14
- Results first posted
- 2022-07-14
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With no Evidence of SARS-CoV-2 Infection | Up to 28 days | Number of participants with no evidence of SARS-CoV-2 infection at or before study day 28. |
| Secondary | Time to no Detection of SARS-CoV-2 | Up to 14 days | Resolution of SARS-CoV-2 infection in the upper respiratory tract as assessed by time (in days) to no detection of SARS-CoV-2 in two upper respiratory samples. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With no Evidence of SARS-CoV-2 Infection | Up to 28 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Time to no Detection of SARS-CoV-2 | Up to 14 days | This outcome was not assessed because all participants were negative at the time of entering study and didn't test positive. No data was collected. |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With no Evidence of SARS-CoV-2 Infection | Peginterferon Lambda Alfa-1a | 2 | Participants | ||
| Number of Participants With no Evidence of SARS-CoV-2 Infection | Placebo | 4 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Peginterferon Lambda Alfa-1a | 2 | |
| Overall Study | STARTED | Placebo | 4 | |
| Overall Study | COMPLETED | Peginterferon Lambda Alfa-1a | 2 | |
| Overall Study | COMPLETED | Placebo | 4 | |
| Overall Study | NOT COMPLETED | Peginterferon Lambda Alfa-1a | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Peginterferon Lambda Alfa-1a | 0 | 2 |
| Total, all-cause mortality | Placebo | 0 | 4 |
| Total, other adverse events | Peginterferon Lambda Alfa-1a | 0 | 2 |
| Total, other adverse events | Placebo | 0 | 4 |
| Total, serious adverse events | Peginterferon Lambda Alfa-1a | 0 | 2 |
| Total, serious adverse events | Placebo | 0 | 4 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Peginterferon Lambda Alfa-1a vs Placebo: Number of Participants With no Evidence of SARS-CoV-2 Infection | Trial comparisons |
| Peginterferon Lambda Alfa-1a vs Placebo: deaths from any cause | Trial comparisons |
| Peginterferon Lambda Alfa-1a vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04344600
GET https://conductscience.org/api/trials/v1/NCT04344600/registered